TY - JOUR
T1 - Myeloperoxidase G-463A polymorphism and lung cancer
T2 - A HuGE Genetic Susceptibility to Environmental Carcinogens pooled analysis
AU - Taioli, Emanuela
AU - Benhamou, Simone
AU - Bouchardy, Christine
AU - Cascorbi, Ingolf
AU - Cajas-Salazar, Nohelia
AU - Dally, Heike
AU - Fong, Kwun M.
AU - Larsen, Jill E.
AU - Le Marchand, Loic
AU - London, Stephanie J.
AU - Risch, Angela
AU - Spitz, Margaret R.
AU - Stucker, Isabelle
AU - Weinshenker, Brian
AU - Wu, Xifeng
AU - Yang, Ping
PY - 2007/2
Y1 - 2007/2
N2 - Myeloperoxidase is a phase I metabolic enzyme that converts the metabolites of benzo[a]pyrene from tobacco smoke into highly reactive epoxides. A polymorphism in the promoter region of myeloperoxidase (463G→A) has been found to be inversely associated with lung cancer; differences in the association with age and gender have been suggested. We conducted a pooled analysis of individual data from 10 studies (3688 cases and 3874 controls) from the Genetic Susceptibility to Environmental Carcinogens database. The odds ratio for lung cancer was 0.88 (95% confidence interval: 0.80-0.97) for the AG variant of myeloperoxidase G-463A polymorphism, and 0.71 (95% confidence interval: 0.57-0.88) for the AA variant after adjusting for smoking, age, gender, and ethnicity. The inverse association between lung cancer and myeloperoxidase G-463A polymorphism was equally found in males and females (odds ratio for the AA genotype 0.73 [95% confidence interval: 0.56-0.96] and 0.67 [95% confidence interval: 0.46-0.98], respectively), without differences in the association according to age in the two genders. The myeloperoxidase G-463A polymorphism was significantly protective in "ever" smokers but not in "never" smokers. Myeloperoxidase is a key enzyme in tobacco-induced carcinogenesis.
AB - Myeloperoxidase is a phase I metabolic enzyme that converts the metabolites of benzo[a]pyrene from tobacco smoke into highly reactive epoxides. A polymorphism in the promoter region of myeloperoxidase (463G→A) has been found to be inversely associated with lung cancer; differences in the association with age and gender have been suggested. We conducted a pooled analysis of individual data from 10 studies (3688 cases and 3874 controls) from the Genetic Susceptibility to Environmental Carcinogens database. The odds ratio for lung cancer was 0.88 (95% confidence interval: 0.80-0.97) for the AG variant of myeloperoxidase G-463A polymorphism, and 0.71 (95% confidence interval: 0.57-0.88) for the AA variant after adjusting for smoking, age, gender, and ethnicity. The inverse association between lung cancer and myeloperoxidase G-463A polymorphism was equally found in males and females (odds ratio for the AA genotype 0.73 [95% confidence interval: 0.56-0.96] and 0.67 [95% confidence interval: 0.46-0.98], respectively), without differences in the association according to age in the two genders. The myeloperoxidase G-463A polymorphism was significantly protective in "ever" smokers but not in "never" smokers. Myeloperoxidase is a key enzyme in tobacco-induced carcinogenesis.
KW - Cooperative studies
KW - Epidemiology
KW - Metabolic gene polymorphisms
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=33847021129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847021129&partnerID=8YFLogxK
U2 - 10.1097/GIM.0b013e31803068b1
DO - 10.1097/GIM.0b013e31803068b1
M3 - Review article
C2 - 17304047
AN - SCOPUS:33847021129
SN - 1098-3600
VL - 9
SP - 67
EP - 73
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 2
ER -